Modern possibilities of tear film stability restoration

1. Jones L., Downie L.E., Korb D. et al. TFOS DEWS II Management and therapy report. Ocular Surface. 2017;15:575–628. DOI: 10.1016/j.jtos.2017.05.006. 2. Бржеский В.В., Егорова Г.Б., Егоров Е.А. Синдром «сухого глаза» и заболевания глазной поверхности: клиника, диагностика, лечение. М.: ГЭОТАР-Медиа; 2016.Brzheskiy V.V., Egorova G.B., Egorov E.A. Dry eye syndrome and ocular surface diseases: clinic, diagnosis, treatment. M.: GEOTAR-Media; 2016 (in Russ.). 3. Zhuang-Yan A., Syed Y.Y. Perfluorohexyloctane ophthalmic solution: A Review in dry eye disease. Drugs. 2024;84(4):441–448. DOI: 10.1007/s40265-024-02016-5. 4. Miura M., Inomata T., Nojiri S. et al. Clinical efficacy of diquafosol sodium 3% versus hyaluronic acid 0.1% in patients with dry eye disease after cataract surgery: a protocol for a single-centre, randomized controlled trial. BMJ Open. 2022;12:e052488. DOI: 10.1136/bmjopen-2021-052488. 5. Ballesteros-Sanches A., Borroni D., De-Hita-Cantalejo C. et al. Efficacy of bilateral OC-01 (varenicline solution) nasal spray in alleviating signs and symptoms of dry eye disease: A systematic review. Cont Lens and Anterior Eye. 2024;47(1):e102097. DOI: 10.1016/j.clae.2023.102097. 6. Бржеский В.В., Голубев С.Ю., Лебедев О.И. и др. Новые возможности комплексной терапии больных с синдромом сухого глаза различной этиологии. Офтальмология. 2020;17(3):481–489. DOI: 10.18008/1816-5095-2020-3-481-489.Brzheskiy V.V., Golubev S.Yu., Lebedev O.I. et al. New Opportunities for Complex Therapy in Patients with Dry Eye Syndrome of Various Etiologies. Ophthalmology in Russia. 2020;17(3):481–489 (in Russ.) DOI: 10.18008/1816-5095-2020-3-481-489. 7. Бржеский В.В., Радхуан М.Р. Сравнительная эффективность методов обтурации слезоотводящих путей в лечении пациентов с синдромом сухого глаза. Вестник офтальмологии. 2019;135(1):12–20. DOI: 10.17116/oftalma201913501112.Brzheskiy V.V., Radhuan M.R. Comparative effectiveness of lacrimal duct obstruction methods in the treatment of patients with dry eye syndrome. Vestnik oftal'mologii. 2019;135(1):12–20 (in Russ.). DOI: 10.17116/oftalma201913501112. 8. Eom Y., Chung S.H., Chung TY. et al. Efficacy and safety of 1% and 2% rebamipide clear solution in dry eye disease: a multicenter randomized trial. BMC Ophthalmol. 2023;23:343. DOI: 10.1186/s12886-023-03004-1. 9. Becker L.C., Bergfeld W.F., Belsito D.V. et al. Final report of the safety assessment of hyaluronic acid, potassium hyaluronate, and sodium hyaluronate. Int J Toxicol. 2009;28(4S):5–67. DOI: 10.1177/1091581809337738. 10. Бржеский В.В., Попов В.Ю. Современные возможности применения натрия гиалуроната в слезозаместительной терапии больных с синдромом «сухого глаза». РМЖ. Клиническая офтальмология. 2018;4:179–185. DOI: 10.21689/2311-7729-2018-18-4-179-185.Brzheskiy V.V., Popov V.Yu. Modern possibilities of sodium hyaluronate in tear substitutive therapy of patients with "dry eye"syndrome. RMJ "Clinical ophthalmology". 2018;4:179–185 (in Russ.). DOI: 10.21689/2311-7729-2018-18-4-179-185. 11. Prosdocimi M., Bevilacqua C. Exogenous hyaluronic acid and wound healing: an updated vision. Panminerva Med. 2012;54(2):129–135. PMID: 22525567. 12. Krasinski R., Tchorzewski H. Hyaluronan-mediated regulation of inflammation. Postepy Hig Med Dosw. (Online). 2007;61:683–689 (in Polish). PMID: 18033205. 13. Бржеский В.В., Бобрышев В.А., Ким Г.Г. Эволюция препаратов искусственной слезы на основе гиалуроновой кислоты. Медицинский совет. 2023;(23):303–309. DOI: 10.21518/ms2023-430.Brzhesky V.V., Bobryshev V.A., Kim G.G. The evolution of artificial tears based on hyaluronic acid. Medical Council. 2023;(23):303–309 (in Russ.). DOI: 10.21518/ms2023-430. 14. Shimojo A.A., Pires A.M., Lichy R. et al. The crosslinking degree controls the mechanical, rheological, and swelling properties of hyaluronic acid microparticles. J Biomed Mater Res. 2015;103:730–737. DOI: 10.1002/jbm.a.35225. 15. Fallacara A., Manfredini S., Durini E., Vertuani S. Hyaluronic acid fillers in soft tissue regeneration. Facial Plast Surg. 2017;33:87–96. DOI: 10.1055/s-0036-1597685. 16. Schanté C.E., Zuber G., Vandamme T.F. Chemical modifications of hyaluronic acid for the synthesis of derivatives for a broad range of biomedical applications. Carbohydrate Polymers. 2011;85(3):469–489. DOI: 10.1016/j.carbpol.2011.03.019. 17. Fallacara A., Vertuani S., Panozzo G. et al. Novel artificial tears containing cross-linked hyaluronic acid: An in vitro re-epithelialization study. Molecules. 2017;22:2104. DOI: 10.3390/molecules22122104. 18. Lai J.Y., Li Y.T. Influence of cross-linker concentration on the functionality of carbodiimide cross-linked gelatin membranes for retinal sheet carriers. J Biomater Sci Polym Ed. 2011;22(1–3):277–295. DOI: 10.1163/092050609X12603600753204. 19. Lu P.L., Lai J.Y., Ma D.H., Hsiue G.H. Carbodiimide cross-linked hyaluronic acid hydrogels as cell sheet delivery vehicles: characterization and interaction with corneal endothelial cells. J Biomater Sci Polym Ed. 2008;19:1–18. DOI: 10.1163/156856208783227695. 20. Leach J.B., Bivens K.A., Collins C.N., Schmidt C.E. Development of photocrosslinkable hyaluronic acid-polyethylene glycol-peptide composite hydrogels for soft tissue engineering. J Biomed Mater Res A. 2004;70(1):74–82. DOI: 10.1002/jbm.a.30063. 21. Schramm C., Spitzer M.S., Henke-Fahle S. et al. The crosslinked biopolymer hyaluronic acid as an artificial vitreous substitute. Invest Ophthalmol Vis Sci. 2012;53:613–621. DOI: 10.1167/iovs.11-7322. 22. Posarelli C., Passani A., Del Re M. et al. Cross-linked hyaluronic acid as tear film substitute. J Ocul Pharmacol Ther. 2019;35(7):381–387. DOI: 10.1089/jop.2018.0151. 23. Yang G., Espandar L., Mamalis N., Prestwich G.D. A cross-linked hyaluronan gel accelerates healing of corneal epithelial abrasion and alkali burn injuries in rabbits. Vet Ophthalmol. 2010;13:144–150. DOI: 10.1111/j.1463-5224.2010.00771.x. 24. Williams D.L., Mann B.K. A сrosslinked HA-based hydrogel ameliorates dry eye symptoms in dogs. Int J Biomater. 2013;2013:460437. DOI: 10.1155/2013/460437. 25. Williams D.L., Mann B.K. Efficacy of a crosslinked hyaluronic acid-based hydrogel as a tear film supplement: a masked controlled study. PLoS One. 2014;9(6):e99766. DOI: 10.1371/journal.pone.0099766. 26. Williams D.L., Wirostko B.M., Gum G., Mann B.K. Topical cross-linked HA-based hydrogel accelerates closure of corneal epithelial defects and repair of stromal ulceration in companion animals. Invest Ophthalmol Vis Sci. 2017;58:4616–4622. DOI: 10.1167/iovs.16-20848. 27. Park S.K., Ha M., Kim E.J. et al. Hyaluronic acid hydrogels crosslinked via blue light-induced thiol-ene reaction for the treatment of rat corneal alkali burn. Regen Ther. 2022;20:51–60. DOI: 10.1016/j.reth.2022.03.005. 28. Cagini C., Torroni G., Fiore T. et al. Tear film stability in Sjogren syndrome patients treated with hyaluronic acid versus crosslinked hyaluronic acid-based eye drops. J Ocul Pharmacol Ther. 2017;33(7):539–542. DOI: 10.1089/jop.2016.0149. 29. Postorino E.I., Rania L., Aragona E. et al. Efficacy of eyedrops containing cross-linked hyaluronic acid and coenzyme Q10 in treating patients with mild to moderate dry eye. Eur J Ophthalmol. 2018;28:25–31. DOI: 10.5301/ejo.5001011. 30. Durrie D.S., Wolsey D., Thompson V. et al. Ability of a new crosslinked polymer ocular bandage gel to accelerate reepithelialization after photorefractive keratectomy. J Cataract Refract Surg. 2018;44:369–375. DOI: 10.1016/j.jcrs.2018.01.018. 31. Eftimov P., Yokoi N., Melo A.M. et al. Interactions of meibum and tears with mucomimetic polymers: a hint towards the interplay between the layers of the tear film. Int J Mol Sci. 2021;22(5):27–47. DOI: 10.3390/ijms22052747. 32. Masmali A.M., Purslow C., Murphy P.J. The tear ferning test: A simple clinical technique to evaluate the ocular tear film. Clin Exp Optom. 2014;97(5):399–406. DOI: 10.1111/cxo.12160. 33. Сомов Е.Е., Бржеский В.В. Слеза (Физиология, методы исследования, клиника). СПб.: Наука; 1994.Somov E.E., Brzheskiy V.V. Lacryma (Physiology, research methods, clinic): SPb.: Nauka; 1994 (in Russ.). 34. Georgiev G.A., Eftimov P., Yokoi N. Contribution of mucins towards the physical properties of the tear film: A modern update. Int J Mol Sci. 2019;20(24):6132. DOI: 10.3390/ijms20246132. 35. Svitova T.F., Lin M.C. Dynamic interfacial properties of human tear-lipid films and their interactions with model-tear proteins in vitro. Adv Colloid Interface Sci. 2016;233:4–24. DOI: 10.1016/j.cis.2015.12.009. 36. Schiffman R., Christianson D., Jacobsen G. et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118(5):615–621. DOI: 10.1001/archopht.118.5.615. 37. Bron A.J., Evans V.E., Smith J.A. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003;22(7):640–650. DOI: 10.1097/00003226-200310000-00008.